Human Albumin as Drug Therapy for Decompensated Cirrhosis: A New Lifesaving Role for an Old Player?
A growing body of evidence suggests known pharmacologic properties of human albumin may contribute to reducing the risk of a range of cirrhosis complications, including bacterial sepsis, irreversible renal injury and death.
New Hemophilia A Treatment Approved by FDA
The U.S. Food and Drug Administration (FDA) has approved Bayer’s Jivi (BAY94-9027) as a preventive treatment for bleeding in hemophilia A.
Neonatal Fc Receptor Antagonist Efgartigimod Sustainably Reduces Circulating IgG Level in Humans
Investigators from the Belgian biotechnology company argenx and U.S. collaborators conducted a PhaseI clinical study to assess a novel modified antibody Fc fragment (efgartigimod) that reduces the circulating IgG level by blocking neonatal Fc receptor-mediated IgG recycling.
The Growing Threat of Antibiotic-Resistant Illnesses
A host of programs continue to be implemented in the United States and globally to address antibiotic-resistant illnesses.
Cinryze Approved for Preventing Pediatric Angioedema Attacks
The U.S. Food and Drug Administration (FDA) has approved Shire’s Cinryze (C1 esterase inhibitor [human]) to prevent angioedema attacks in children 6 years and older with hereditary angioedema.
Second JAK Inhibitor Drug for RA Approved by FDA
The U.S. Food and Drug Administration (FDA) has approved Incyte Corp.’s Olumiant (baricitinib) 2 mg once-daily oral medication to treat adults with moderately to severe active rheumatoid arthritis.
FDA Approves Marijuana-Based Drug for Seizures
The U.S. Food and Drug Administration has approved the first prescription drug made from marijuana.
Rituxan Approved to Treat Severe Pemphigus Vulgaris
The U.S. Food and Drug Administration has approved Genentech’s Rituxan (rituximab) to treat moderate-tosevere phemphigus vulgaris.
FDA Approves Fast-Acting, Single-Dose Flu Medication
The U.S. Food and Drug Administration (FDA) has approved a new, single-dose medication to treat people 12 years and older who have had the flu for no more than 48 hours.
FDA Approves First Treatment for High-Risk Prostate Cancer
The U.S. Food and Drug Administration has approved Erleada (apalutamide) to treat men with prostate cancer that has not yet spread but has a quickly rising PSA level while on treatment with hormone therapy, which causes concern for cancer growth and spread.